Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results
MWN-AI** Summary
Rafael Holdings, Inc. (NYSE: RFL) announced its financial results for the fourth quarter and full year of fiscal 2025, concluding on July 31, 2025. The company recorded a net loss of $12.1 million in Q4, or $0.28 per share, compared to a net loss of $4.5 million, or $0.19 per share, in the same quarter last year. This increase is largely attributed to the consolidation of expenses from Cyclo Therapeutics, which Rafael acquired earlier in 2025.
For the full year, Rafael reported a net loss of $30.5 million, or $1.04 per share, showing improvement from a net loss of $34.4 million, or $1.45 per share in the prior year. The decrease in net loss was partially due to an $89.9 million in-process R&D expense related to the acquisition of Cornerstone and a $31.3 million recovery of receivables from Cornerstone in the previous year. Research and development expenses surged to $12.8 million for the fiscal year, up from $4.2 million, reflecting increased activity at Cyclo and the consolidation of Cornerstone and Day Three.
In terms of financial positioning, Rafael Holdings strengthened its balance sheet with a $25 million rights offering closed in June 2025. As of the fiscal year-end, the company had cash and cash equivalents totaling $52.8 million.
The company's lead product, Trappsol® Cyclo™, is undergoing a pivotal Phase 3 clinical trial for treating Niemann-Pick Disease Type C1, with ongoing support from a Data Monitoring Committee. With recent leadership appointments and a focus on enhancing its portfolio, Rafael Holdings is poised for strategic advancements in the coming period.
MWN-AI** Analysis
Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-W) has delivered its financial results for the fourth quarter and full year of fiscal 2025, showing notable shifts in both performance and strategy. The company continues to focus on its pivotal Phase 3 clinical trial of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1, supported by feedback from the Data Monitoring Committee (DMC). The sustained commitment to this trial amidst rising expenditures indicates a robust pipeline and potential value creation for stakeholders.
The financial results highlight an increased net loss of $12.1 million for the latest quarter, up from $4.5 million year-over-year, primarily attributed to the consolidation of Cyclo Therapeutics post-acquisition. While there is immediate concern surrounding the rising losses, the completion of a $25 million rights offering strengthens Rafael's liquidity position, providing necessary capital to support ongoing and future research initiatives.
Investors should also reflect on the operational changes following Joshua Fine’s election as COO, alongside the strengthened board with experienced additions. Leadership changes often signal a shift toward strategic agility within biopharmaceuticals—an encouraging sign for long-term performance.
Importantly, while escalating R&D expenses ($7.5 million for the quarter) reflect increased commitment to clinical trials, investors need to balance this with the realization of potential revenue streams, which remain modest ($350,000 for the quarter). A strategic emphasis on cost management must accompany ongoing R&D to mitigate further losses.
Looking ahead, Rafael Holdings' focus on rare disease treatment could position it favorably in a market with diminishing competition yet high unmet medical need. Investors should approach Rafael with a long-term perspective, weighing the risks of ongoing losses against the promising potential of its therapeutic pipeline and improved financial footing. Investors may look to accumulate shares at dips, fostering a position that could yield substantial returns as clinical milestones are achieved.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee (DMC) following their review of prespecified safety and efficacy date at 48 weeks
On August 4, 2025, Joshua Fine was elected as the Company’s Chief Operating Officer
NEWARK, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-W), today reported its financial results for the fourth quarter and full fiscal year 2025 ended July 31, 2025.
“We are pleased with the continued progress of our pivotal Phase 3 TransportNPC ™ study evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which we believe could provide an important new treatment for option for patients suffering from this rare and fatal genetic disease,” said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings. Mr. Jonas added, “We enhanced our financial position with the closing of a $25 million rights offering in June, which positions our Company well to advance the Trappsol ® Cyclo™ program and invest in additional opportunities we may identify. I would also like to take this opportunity to congratulate Joshua Fine on his appointment as the Company’s Chief Operating Officer, Alan Grayson on his addition to our Board of Directors and Markus Sieger on being named as Chair of our Audit Committee. I look forward to their important contributions towards advancing the Company and driving value for all stakeholders.”
Rafael Holdings, Inc. Fourth Quarter Fiscal Year 2025 Financial Results
As of July 31, 2025, we had cash and cash equivalents of $52.8 million. On June 4, 2025, the Company closed a $25 million rights offering, which included the funding of the backstop commitment in the amount of $21.0 million by the Jonas family.
For the three months ended July 31, 2025, we recorded a net loss attributable to Rafael Holdings of $12.1 million, or $0.28 per share, versus a net loss of $4.5 million, or $0.19 per share in the year ago period. The year over year increase in net loss is attributable to the consolidation of Cyclo Therapeutic’s expenses following the acquisition of Cyclo in March 2025 and the activity of Cornerstone and Day Three which were consolidated with Rafael Holdings during fiscal 2024.
Research and development expenses were $7.5 million for the three months ended July 31, 2025, compared to $1.5 million in the year ago period. The year over year increase relates to the inclusion in the current year period of spending at Cyclo following the March 2025 acquisition and the activity of Cornerstone and Day Three which were consolidated with Rafael Holdings during fiscal 2024.
General and administrative expenses were $5.5 million for the three months ended July 31, 2025, compared to $2.3 million in the year ago period. The year over year increase relates to the inclusion of expenses at Cyclo following closing of the acquisition, and the activity of Cornerstone and Day Three, following their consolidation.
Rafael Holdings, Inc. Full Year Fiscal Year 2025 Financial Results
For the twelve months ended July 31, 2025, we recorded a net loss attributable to Rafael Holdings of $30.5 million, or $1.04 per share, versus a net loss of $34.4 million, or $1.45 per share in the year ago period. The year over year decrease in net loss is attributable to in-process R&D expense of $89.9 million related to the acquisition (when we increased our ownership position) of Cornerstone netted with a $31.3 million recovery of receivables from Cornerstone in the year ago period, $5.9 million in unrealized gains on the Company’s investment in Cyclo equity and the inclusion of Cyclo following closing of the acquisition in March 2025 and the activity of Cornerstone and Day Three, following their consolidation.
Research and development expenses were $12.8 million for the twelve months ended July 31, 2025, compared to $4.2 million in the year ago period. The year over year increase relates to the inclusion of spending at Cyclo following the March 2025 acquisition of with Cyclo, and the activity of Cornerstone and Day Three, which were consolidated with Rafael Holdings during fiscal 2024.
For the twelve months ended July 31, 2025, general and administrative expenses were $13.8 million compared to $8.9 million in the same period in the prior year. The year over year increase relates to spending at Cyclo following the acquisition, and the activity of Cornerstone and Day Three, following their consolidation.
About Rafael Holdings, Inc.
Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early stage companies that develop pharmaceuticals and medical devices. Our lead candidate is Trappsol® Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (“NPC1”), a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries. Our lead candidate, Trappsol® Cyclo™, is the subject of an ongoing pivotal Phase 3 clinical trial.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended July 31, 2024, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Contact:
Barbara Ryan
Barbara.ryan@rafaelholdings.com
(203) 274-2825
| RAFAEL HOLDINGS, INC. | ||||||||
| CONSOLIDATED BALANCE SHEETS | ||||||||
| (in thousands, except share and per share data) | ||||||||
| July 31, 2025 | July 31, 2024 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | $ | 52,769 | $ | 2,675 | ||||
| Available-for-sale securities | — | 63,265 | ||||||
| Prepaid clinical trial costs | 1,045 | — | ||||||
| Interest receivable | — | 515 | ||||||
| Convertible notes receivable, due from Cyclo | — | 5,191 | ||||||
| Other receivables | 1,206 | — | ||||||
| Accounts receivable, net of allowance for credit losses of $245 at July 31, 2025 and July 31, 2024 | 627 | 426 | ||||||
| Inventory | 281 | — | ||||||
| Prepaid expenses and other current assets | 786 | 430 | ||||||
| Total current assets | 56,714 | 72,502 | ||||||
| Property and equipment, net | 1,596 | 2,120 | ||||||
| Investments – Hedge Funds | — | 2,547 | ||||||
| Investments – Cyclo | — | 12,010 | ||||||
| Convertible notes receivable classified as available-for-sale | 1,858 | 1,146 | ||||||
| Goodwill | 19,939 | 3,050 | ||||||
| Intangible assets, net | 994 | 1,847 | ||||||
| In-process research and development | 31,575 | 1,575 | ||||||
| Non-current prepaid clinical trial costs | 1,399 | — | ||||||
| Other assets | 34 | 35 | ||||||
| TOTAL ASSETS | $ | 114,109 | $ | 96,832 | ||||
| LIABILITIES AND EQUITY | ||||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable | $ | 6,893 | $ | 2,556 | ||||
| Accrued expenses | 3,304 | 1,798 | ||||||
| Convertible notes payable | 614 | 614 | ||||||
| Other current liabilities | 66 | 113 | ||||||
| Due to related parties | 723 | 733 | ||||||
| Installment note payable | — | 1,700 | ||||||
| Total current liabilities | 11,600 | 7,514 | ||||||
| Accrued expenses, noncurrent | 3,895 | 2,982 | ||||||
| Convertible notes payable, noncurrent | 78 | 73 | ||||||
| Other liabilities | 27 | 5 | ||||||
| Deferred income tax liability | 138 | — | ||||||
| TOTAL LIABILITIES | $ | 15,738 | $ | 10,574 | ||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| EQUITY | ||||||||
| Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of July 31, 2025 and July 31, 2024 | 8 | 8 | ||||||
| Class B common stock, $0.01 par value; 200,000,000 shares authorized, 50,789,697 issued and outstanding (excluding treasury shares of 101,487) as of July 31, 2025, and 24,142,535 issued and 23,819,948 outstanding (excluding treasury shares of 101,487) as of July 31, 2024 | 508 | 238 | ||||||
| Additional paid-in capital | 322,161 | 280,048 | ||||||
| Accumulated deficit | (232,263 | ) | (201,743 | ) | ||||
| Treasury stock, at cost; 101,487 Class B shares as of July 31, 2025 and July 31, 2024 | (168 | ) | (168 | ) | ||||
| Accumulated other comprehensive income related to unrealized income on available-for-sale securities | 358 | 111 | ||||||
| Accumulated other comprehensive income related to foreign currency translation adjustment | 3,787 | 3,691 | ||||||
| Total equity attributable to Rafael Holdings, Inc. | 94,391 | 82,185 | ||||||
| Noncontrolling interests | 3,980 | 4,073 | ||||||
| TOTAL EQUITY | 98,371 | 86,258 | ||||||
| TOTAL LIABILITIES AND EQUITY | $ | 114,109 | $ | 96,832 | ||||
| RAFAEL HOLDINGS, INC. | |||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) | |||||||||||||||
| (in thousands, except share and per share data) | |||||||||||||||
| Three Months Ended July 31, | Year Ended July 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenues | $ | 350 | $ | 165 | $ | 917 | $ | 637 | |||||||
| Cost of infusion Technology revenue | - | 69 | 106 | 154 | |||||||||||
| Cost of product revenue | 19 | - | 28 | - | |||||||||||
| G&A Expenses | 5,497 | 2,330 | 13,781 | 8,854 | |||||||||||
| R&D Expenses | 7,547 | 1,543 | 12,823 | 4,170 | |||||||||||
| In-process research and development expense | - | - | - | 89,861 | |||||||||||
| Depreciation and amortization | 50 | 68 | 288 | 225 | |||||||||||
| Loss on impairment of goodwill | - | - | 3,050 | - | |||||||||||
| Operating Loss | (12,763 | ) | (3,845 | ) | (29,159 | ) | (102,627 | ) | |||||||
| Interest income | 467 | 606 | 1,996 | 2,383 | |||||||||||
| Loss on initial investment in Day Three upon acquisition | - | - | - | (1,633 | ) | ||||||||||
| Realized gain on available-for-sale securities | - | 251 | 178 | 1,772 | |||||||||||
| Realized loss on investment in equity securities | - | - | - | (46 | ) | ||||||||||
| Realized gain on investment - Cyclo | - | - | - | 424 | |||||||||||
| Unrealized (loss) gain on investment - Cyclo | - | (3,162 | ) | (5,144 | ) | 37 | |||||||||
| Unrealized (loss) gain on convertible notes receivable, due from Cyclo | - | 1,191 | (719 | ) | 1,191 | ||||||||||
| Unrealized gain on investment - Hedge Funds | - | 181 | - | 63 | |||||||||||
| Recovery of receivables from Cornerstone | - | - | - | 31,305 | |||||||||||
| Interest expense | (168 | ) | (163 | ) | (658 | ) | (248 | ) | |||||||
| Other income, net | 236 | - | 310 | 118 | |||||||||||
| Loss before incomes taxes | (12,228 | ) | (4,941 | ) | (33,196 | ) | (67,261 | ) | |||||||
| Benefit from taxes | 174 | 87 | 2,553 | 2,680 | |||||||||||
| Equity in loss of Day Three | - | - | - | (422 | ) | ||||||||||
| Consolidated net loss | (12,054 | ) | (4,854 | ) | (30,643 | ) | (65,003 | ) | |||||||
| Consolidated net loss | (12,054 | ) | (4,854 | ) | (30,643 | ) | (65,003 | ) | |||||||
| Net loss attributable to noncontrolling interests | 40 | (386 | ) | (123 | ) | (30,593 | ) | ||||||||
| Net loss attributable to Rafael Holdings, Inc. | $ | (12,094 | ) | $ | (4,468 | ) | $ | (30,520 | ) | $ | (34,410 | ) | |||
| Loss per share attributable to common stockholders | |||||||||||||||
| Basic and diluted | $ | (0.28 | ) | $ | (0.19 | ) | $ | (1.04 | ) | $ | (1.45 | ) | |||
| Weighted average number of shares used in calculation of loss per share - basic and diluted | 43,011,360 | 23,916,839 | 29,422,221 | 23,745,516 | |||||||||||
FAQ**
What are the key milestones expected for the ongoing Phase 3 TransportNPC™ trial of Trappsol® Cyclo™ in Niemann-Pick Disease Type C1 that Rafael Holdings Inc. Class B RFL aims to achieve in the coming months?
How does Rafael Holdings Inc. Class B RFL plan to utilize the cash and equivalents of $52.8 million reported as of July 31, 2025, to advance the Trappsol® Cyclo™ program and other pipeline opportunities?
Given the increased R&D and G&A expenses following the Cyclo acquisition, what strategies does Rafael Holdings Inc. Class B RFL have in place to manage costs while ensuring successful clinical trial outcomes?
What impact does the ongoing Phase 3 trial's results have on Rafael Holdings Inc. Class B RFL's valuation and potential stock performance, particularly in light of the financial losses reported?
**MWN-AI FAQ is based on asking OpenAI questions about Rafael Holdings Inc. Class B (NYSE: RFL).
NASDAQ: RFL
RFL Trading
0.0% G/L:
$1.50 Last:
28,910 Volume:
$1.47 Open:
